Cardiovascular – Renal Drugs : Antiarrhythmics
OCORA2 “Coralan FC tablet” 5.39 mg/tab
適應症：治療慢性心衰竭。適用於治療紐約心臟協會(NYHA)分級第II到III級、收縮性功能不全、竇性心律且每分鐘心跳速率≧75的慢性心衰竭患者，且須使用於對β-阻斷劑為禁忌症或不耐受時。
Usual dose:
Heart failure, chronic: Initial, 5 mg twice daily; after 2 weeks, adjust based on heart rate; for resting rate greater than 60 beats per minute (bpm), increase dose by 2.5 mg twice daily; for 50 to 60 bpm, continue current dose; for less than 50 bpm or for signs or symptoms of bradycardia, decrease dose by 2.5 mg twice daily; max. dose, 7.5 mg twice daily.
Stable angina, chronic, In combination with beta-blocker therapy: 5 mg twice daily for 2 months, then increase to 7.5 mg twice daily if heart rate is at least 50 beats per minute; used in combination with atenolol 50 mg once daily (study dosing).
Contraindication: Acute decompensated heart failure, concomitant use with strong cyp3a4 inhibitors, pacemaker dependent, resting heart rate below 60 beats per minute before treatment, severe hepatic impairment, severe hypotension (less than 90/50 mmhg). Sick sinus syndrome, sinoatrial block, or third-degree atrioventricular block, except in presence of functioning demand pacemaker.
Adverse effect:
Common: Atrial fibrillation, bradyarrhythmia.